Company Profile of Hangzhou Weitai Biological Pharmaceutical Co.,Ltd.

Weitai Bio-Pharmaceutical (Hangzhou) Co., LTD., founded in 2018, is a high-tech enterprise with synthetic biotechnology as the core and green bio-intelligent manufacturing as the direction. It is engaged in the research and development and large-scale production of biological enzyme engineering and nucleotide. At present, the company has its own huge enzyme library and hundreds of gene strains (including enzyme engineering, strain engineering, biocatalytic engineering, fermentation engineering, as well as the complete series of nucleotides, deoxygenation series, poly-phosphate series). It takes the lead in applying biosynthesis technology to the commercial production of "life molecules" catalyzed by nucleotides and biological enzymes as monomer. Its products are applied in seven fields, including biomedicine, nutrition and health, functional food, green agriculture, veterinary medicine, daily chemical care and cosmetics. It is one of the leading enterprises in scale production and technology in the field of synthetic biology in China. In 2018, the company was listed as a key investment project of "high, new and advanced" by Anhui Provincial Department of Science and Technology. In December of the same year, the production base of Weitai Pharmaceutical (Maanshan) Co., LTD., located in Maanshan Economic Development Zone, was established. The first phase of production is 70 million yuan. The park covers an area of 30 mu, with 4500 square meters of production workshop and 2500 square meters of research and development, office area; Purchase a large number of advanced production equipment and high precision testing instruments and set up a strict and scientific quality management system; At the same time, it has absorbed many high-tech talents and experts in the field of synthetic biology, and the total investment of the project is 110 million yuan. In line with the business philosophy of "customer first, quality first, integrity-based", the company is committed to the development and industrialization of biosynthetic technology and green manufacturing, replacing the traditional chemical production process, improving production efficiency, reducing the use of flammable, explosive and violent drugs, reducing the discharge of three wastes, and saving a large amount of production costs for pharmaceutical enterprises.